Side Effects of rucaparib: A Synthesis of Findings from 16 Studies

  1. Home
  2. Side Effects of rucaparib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of rucaparib: A Synthesis of Findings from 16 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of rucaparib: A Synthesis of Findings from 16 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Rucaparib, a PARP inhibitor, has shown promising results in treating patients with platinum-sensitive recurrent ovarian cancer, particularly those with BRCA1/2 mutations. 9 , 7 , 6 . These studies have demonstrated that rucaparib can improve response rates and extend progression-free survival in these patients. 9 , 7 . However, like other chemotherapies, rucaparib can have side effects.

Reasons for Side Effects

Rucaparib works by inhibiting DNA repair pathways, which are crucial for cell survival and growth. 10 . While this mechanism effectively targets cancer cells, it can also affect healthy cells, leading to side effects.

Common Side Effects

Fatigue

Fatigue is one of the most common side effects reported with rucaparib. 9 , 6 . This may be due to rucaparib's disruption of DNA repair pathways, which can affect cellular energy production.

Nausea and Vomiting

Rucaparib can also cause gastrointestinal side effects such as nausea and vomiting. 9 , 6 . This is likely related to rucaparib's impact on cells within the digestive system.

Anemia

Anemia, a condition characterized by low red blood cell count, has been observed in patients receiving rucaparib. 9 , 6 . This could be attributed to rucaparib's interference with red blood cell production.

Liver Function Abnormalities

Some patients may experience liver function abnormalities while on rucaparib. 9 , 6 . This could be due to rucaparib's effects on liver cells.

Thrombocytopenia

Thrombocytopenia, a decrease in platelet count, is another potential side effect of rucaparib. 6 . This could be a result of rucaparib's impact on platelet production.

Side Effect Management

Fatigue

To manage fatigue, adequate rest is crucial. 6 . Lifestyle modifications such as dietary adjustments and exercise can also help. 6 . Consulting a doctor may lead to the prescription of medications to reduce fatigue.

Nausea and Vomiting

Anti-nausea medications may be prescribed by a doctor to alleviate nausea and vomiting. 6 . Lifestyle adjustments, such as dietary and exercise changes, can also be beneficial. 6 . Staying adequately hydrated is essential.

Anemia

Blood transfusions may be necessary to manage anemia. 6 . Doctors may also prescribe medications to reduce the symptoms of anemia.

Liver Function Abnormalities

To address liver function abnormalities, doctors may temporarily stop rucaparib administration. 6 . Medications to improve liver function may also be prescribed.

Thrombocytopenia

To manage thrombocytopenia, doctors may temporarily suspend rucaparib treatment. 6 . Medications to boost platelet production may also be prescribed.

Comparison Between Studies

Commonalities Between Studies

These studies consistently demonstrate the effectiveness and safety of rucaparib in treating ovarian cancer patients. 9 , 7 , 6 . Additionally, these studies indicate that the most frequent side effects associated with rucaparib are fatigue, nausea, vomiting, anemia, and liver function abnormalities. 9 , 6 .

Differences Between Studies

These studies have employed varying rucaparib dosages and durations of administration. 9 , 7 , 6 . Consequently, the effectiveness and frequency of side effects observed in each study may differ.

Cautions Regarding Real-World Applications

Rucaparib is a promising treatment option for patients with platinum-sensitive high-grade serous ovarian cancer with BRCA1/2 mutations, but it is important to acknowledge the potential for side effects. 9 , 7 , 6 . Prior to commencing rucaparib treatment, consulting with a doctor and carefully weighing the risks and benefits is crucial.

Limitations of Current Research

The number of studies evaluating the effectiveness and safety of rucaparib remains limited. 9 , 7 , 6 . Furthermore, sufficient data regarding the long-term effects of rucaparib is lacking. 9 , 7 , 6 .

Future Research Directions

Studies are needed to assess the long-term effects of rucaparib. 9 , 7 , 6 . Research is also required to enhance the efficacy of rucaparib and mitigate its side effects.

Conclusion

Rucaparib has emerged as a promising treatment for patients with platinum-sensitive high-grade serous ovarian cancer with BRCA1/2 mutations. 9 , 7 , 6 . However, it is essential to recognize the potential for side effects. 9 , 7 , 6 . Before starting rucaparib treatment, consulting with a doctor and carefully considering the risks and benefits is crucial.

Literature analysis of 16 papers
Positive Content
15
Neutral Content
1
Negative Content
0
Article Type
1
1
2
8
16
1.

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting.

Author: TookmanLaura, KrellJonathan, NkolobeBaleseng, BurleyLaura, McNeishIain A

Maintenance
Ovarian cancer treatment
Anemia
Fatigue
Liver enzyme elevations
Nausea
Vomiting

PARP inhibitors are a new type of cancer drug that is showing promise in the treatment of ovarian cancer. This paper discusses some of the real-world challenges and side effects of rucaparib, a PARP inhibitor. The authors provide guidance on how a multidisciplinary team can effectively manage these side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.

Author: PeipertJohn Devin, GobleSandra, IsaacsonJeff, TangXiaodan, WallaceKatrine, ColemanRobert L, LedermannJonathan A, CellaDavid

Rucaparib side effects

This study compared the impact of maintenance rucaparib with placebo on patient-reported outcomes in patients with ovarian carcinoma. Rucaparib was associated with a higher risk of deterioration in patient-reported outcomes, including physical symptoms and overall health status.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.

Author: SandhuDaranjit, AntolinAlbert A, CoxAnthony R, JonesAlan M

Anemia
Diarrhea
Fatigue
Hepatotoxicity
Hypertension
Hypothyroidism
Myelosuppression
Nausea
Neutropenia
Thrombocytopenia
Vomiting

The polypharmacology of PARP inhibitors, despite their similar mode of action, influences their adverse drug reaction (ADR) profile. This suggests that the choice of PARP inhibitor should consider the specific ADR profile of each drug.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.

Author: RuscitoIlary, BellatiFilippo, Ray-CoquardIsabelle, MirzaMansoor Raza, du BoisAndreas, GasparriMaria Luisa, CostanziFlavia, De MarcoMaria Paola, NutiMarianna, CasertaDonatella, PignataSandro, DorigoOliver, SehouliJalid, BraicuElena Ioana

ovarian cancer treatment

PARP inhibitors are a new class of targeted agents that are effective and safe for the treatment of recurrent and primary advanced ovarian cancer.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

How safe is rucaparib in ovarian cancer?

Author: CosgroveCasey M, O'MalleyDavid M

Prolongation of survival
Serum creatinine increases
Transaminitis

Rucaparib is a promising therapeutic option for women with recurrent ovarian cancer. The side effect profile of rucaparib is similar to or more favorable than other PARP inhibitors. Clinicians should be prepared for increasing utilization of PARP inhibitors in the recurrent setting and potentially upfront usage.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Current status of poly(ADP-ribose) polymerase inhibitors and future directions.

Author: OhmotoAkihiro, YachidaShinichi

Cancer treatment
PARP inhibitor
Long-term side effects

This review summarizes preclinical and clinical data for PARP inhibitors and discusses their potential applications in treating various malignancies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Carcinoma or Other Solid Tumors.

Author: KristeleitRebecca, ShapiroGeoffrey I, BurrisHoward A, OzaAmit M, LoRussoPatricia, PatelManish R, DomchekSusan M, BalmañaJudith, DrewYvette, ChenLee-May, SafraTamar, MontesAna, GiordanoHeidi, MaloneyLara, GobleSandra, IsaacsonJeff, XiaoJim, BorrowJen, RolfeLindsey, Shapira-FrommerRonnie

Tolerable
Tumor response
Anemia
Fatigue
Liver enzyme elevation
Nausea
Vomiting

Rucaparib is a PARP inhibitor that is used to treat certain types of cancer, including ovarian cancer. This study evaluated the safety and efficacy of oral rucaparib in patients with advanced solid tumors. The study found that rucaparib was well tolerated and had promising activity in patients with platinum-sensitive, high-grade ovarian carcinoma associated with BRCA1/2 mutations.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?

Author: AliMajid, TelferBrian A, McCruddenCian, O'RourkeMartin, ThomasHuw D, KamjooMarzieh, KyleSuzanne, RobsonTracy, ShawChris, HirstDavid G, CurtinNicola J, WilliamsKaye J

Cancer treatment
Enhanced chemo efficacy
Unknown

AG014699, a PARP inhibitor, exhibits a novel vascular-based activity, enhancing chemosensitization and widening its clinical application.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

12.

Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.

Author: O'SullivanJoe M, AbramowitzElliot, Sierra-ScacalossiLen

Maximizes benefit
Prolongs life

This article provides an overview of current systemic treatments available for metastatic castration-resistant prostate cancer (mCRPC) and reviews studies investigating the optimal timing for using radium-223. The aim is to illustrate possible systemic treatment sequences to maximize benefit from radium-223 therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Recent advances in the molecular targeted drugs for prostate cancer.

Author: GaoPudong, LiTao, ZhangKuiyuan, LuoGuangheng

Prostate cancer treatment
Adverse drug reactions
Hormone resistance

This study explores the challenges of treating advanced prostate cancer (PCa) in China, including refractory hormone resistance and adverse drug reactions.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Targeted therapy of ovarian cancer including immune check point inhibitor.

Author: KimJin Young, ChoChi Heum, SongHong Suk

Improved survival
Increased side effects

Ovarian cancer is a serious disease, and many patients are diagnosed at a late stage. This study reviews the current treatment options for ovarian cancer, including the use of targeted therapies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.

Author: MullenMary M, KurokiLindsay M, ThakerPremal H

Anti-angiogenesis therapy
EOC treatment
PARP inhibitor maintenance
Platinum-free interval
Bevacizumab side effects
Cediranib side effects
EOC recurrence
Trebananib side effects

This review discusses pivotal trials establishing platinum-based combination chemotherapy as the standard of care for epithelial ovarian cancer and addresses the utility of increasing a patient's platinum-free interval.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.